Expertise in
25
conditions

Dr. David L. Becton

Hematology | Oncology
Arkansas Children's Hospital
1 Childrens Way, 
Little Rock, AR 
Clinical Trials:Currently Recruiting for 7 Trials
Accepting New Patients
Expertise in
25
conditions
Arkansas Children's Hospital
1 Childrens Way, 
Little Rock, AR 

Overview

David Becton is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas.

Dr. Becton is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hepatoblastoma, Langerhans Cell Histiocytosis, Ependymoma, Rhabdoid Tumor, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 81 clinical trials. Dr. Becton is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in AR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMO Partners
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Arkansas Children's Hospital
1 Childrens Way, Little Rock, AR 72202

Additional Areas of Focus

Dr. Becton has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

81 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure
Study Phase: Phase 1/Phase 2
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation, Other
Study Drugs: Carboplatin, Etoposide, Filgrastim, Ifosfamide, Mesna, Pegfilgrastim, Thiotepa
Study Phase: Phase 2
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
View 3 Less Clinical Trials

7 Total Publications

Cerebrovascular Accidents are Associated With Increased Rates of Anxiety and Depression in People With Sickle Cell Disease: A National Database Study.
Cerebrovascular Accidents are Associated With Increased Rates of Anxiety and Depression in People With Sickle Cell Disease: A National Database Study.
Journal: Pediatric blood & cancer
Published: September 17, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (1.8 miles away)
501-526-6990
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Sharmilan Thanendrarajan is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Thanendrarajan is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
7
conditions
Dr. Jason E. Farrar
Hematology | Oncology
Expertise in
7
conditions
Dr. Jason E. Farrar
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (1.8 miles away)
501-686-5140
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jason Farrar is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Farrar is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Pure Red Cell Aplasia, Aplastic Anemia, Childhood Acute Myeloid Leukemia, and Transient Erythroblastopenia of Childhood. Dr. Farrar is currently accepting new patients.

Expertise in
30
conditions
Dr. Frits Van Rhee
Hematology | Oncology
Expertise in
30
conditions
Dr. Frits Van Rhee
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (1.8 miles away)
501-686-8000
Languages Spoken:
English, Dutch
See accepted insurances
Accepting New Patients
Offers Telehealth

Frits Van Rhee is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Van Rhee is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Van Rhee is currently accepting new patients.

Frequently Asked Questions about Dr. David L. Becton

How do I make an appointment with Dr. David L. Becton?

You can book an appointment with Dr. David L. Becton by calling their office at 501-364-1494. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David L. Becton a top-rated expert for Hepatoblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David L. Becton is classified as an Advanced expert for Hepatoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David L. Becton specialize in?

While Dr. David L. Becton is a Hematology, they have specific expertise in Hepatoblastoma, Langerhans Cell Histiocytosis, and Ependymoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. David L. Becton participate in research or clinical trials?

Yes. Dr. David L. Becton has published 7 articles and abstracts on conditions like Hepatoblastoma. You can view a list of Dr. David L. Becton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David L. Becton accept my insurance?

Dr. David L. Becton accepts most major insurance plans, including Arkansas Health and Wellness and Blue Cross Blue Shield. We recommend calling the office directly at 501-364-1494 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Becton's expertise for a condition
ConditionClose
      View All 25 Advanced Conditions
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile